publication . Article . 2021

Atypical hemolytic uremic syndrome in high-risk neuroblastoma patient: case report

A. Yu. Smirnova; Yu. V. Dinikina; A. A. Tereshina; E. P. Evsutina; M. B. Belogurova;
Open Access
  • Published: 14 Apr 2021 Journal: Oncohematology, volume 16, pages 31-35 (issn: 1818-8346, eissn: 2413-4023, Copyright policy)
  • Publisher: Publishing House ABV Press
Abstract
Atypical hemolytic uremic syndrome is a rare disorder uncontrolled complement activation, which is classically manifested by anemia, thrombocytopenia and renal failure. Extrarenal manifestations are observed in 20 % of patients, most of which are associated with damage of the central nervous system. Eculizumab is effective treatment option. The article describes a case report of the severe atypical hemolytic uremic syndrome in a 20 m. o. patient who received immunotherapy with anti-GD2 antibodies (dinutuximab beta) for a high-risk neuroblastoma.
Persistent Identifiers
Subjects
free text keywords: Oncology, Hematology, atypical hemolytic uremic syndrome, neuroblastoma, risk factor, immunotherapy, Diseases of the blood and blood-forming organs, RC633-647.5
Any information missing or wrong?Report an Issue